page header

Contents  ·  Introduction  ·  Learning  Objectives  ·  Textbook  ·  Lectures  ·  Procedures  ·  Final Exam  ·  Library  ·  Laboratory  ·  Pharmacy  ·  Imaging  ·  Forms  ·  Videos  ·  About  ·  Contact Us

Atenolol (Tenormin)

Category:

  • Nervous system

Description:

  • Antihypertensive, antianginal, class II antidysrhythmic: (beta blocker)

Indications:

  • Angina pectoris due to coronary atherosclerosus,

  • Hypertension, acute MI

  • Several non-FDA approved uses

Contraindications:

  • Cardiogenic shock, 2nd or 3rd degree heart block, sinus bradycardia

  • CHF unless secondary to a tachyarrhythmia treatable with beta-blockers, overt cardiac failure

Precautions:

  • Pregnancy category C

  • Major surgery, diabetes mellitus, renal disease, thyroid disease, COPD, asthma

  • Well compensated heart failure, abrupt withdrawal, peripheral vascular disease

  • Do not discontinue drug abruptly, may precipitate angina

Adverse Reactions (Side Effects):

  • CNS: depression, dizziness, drowsiness, fatigue, hallucinations, insomnia, lethargy, memory loss, mental changes, strange dreams

  • CV: bradycardia, CHF, cold extremities, postural hypotension, profound hypotension, 2nd and 3rd degree heart block

  • EENT: dry burning eyes, sore throat visual disturbances

  • GI: diarrhea, dry mouth, ischemic colitis, mesenteric arterial thrombosis, nausea, vomiting

  • GU: impotence, sexual dysfunction

  • HEME: agranulocytosis, thrombocytopenia

  • METAB: hyperglycemia, hyperlipidemia, masked hypoglycemic response

  • RESP: bronchospasm, dyspnea, wheezing

  • SKIN: alopecia, pruritis, rash

 

Dosage:

Administered orally and intravenously

  • Adult: 

    • IV 

      • 5mg over 5 min

      • repeat in 10 minutes if initial dose is well tolerated

      • then start PO dose 10 minutes after last IV dose

    • PO 

      • 50mg daily

      • increase every 1-2 weeks to 100mg daily

      • may increase to 200mg daily for angina

  • Child: 

    • PO 

      • initial 1-1.2 mg/kg/dose given daily

      • maximum 2 mg/kg/day

 

 

 


The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks

Source: Operational Medicine 2001,  Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300

This information is provided by The Brookside Associates.  The Brookside Associates, LLC. is a private organization, not affiliated with any governmental agency. The opinions presented here are those of the author and do not necessarily represent the opinions of the Brookside Associates or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. All material presented here is unclassified.

C. 2009, 2014, All Rights Reserved

brookside associates logo

 

 

 

Advertise on this site